MX2019004482A - Metodo para producir una preparacion de inmunoglobulina con un rendimiento mejorado. - Google Patents

Metodo para producir una preparacion de inmunoglobulina con un rendimiento mejorado.

Info

Publication number
MX2019004482A
MX2019004482A MX2019004482A MX2019004482A MX2019004482A MX 2019004482 A MX2019004482 A MX 2019004482A MX 2019004482 A MX2019004482 A MX 2019004482A MX 2019004482 A MX2019004482 A MX 2019004482A MX 2019004482 A MX2019004482 A MX 2019004482A
Authority
MX
Mexico
Prior art keywords
present
plasma
preparing
igg composition
methods
Prior art date
Application number
MX2019004482A
Other languages
English (en)
Inventor
Schwarz Hans-Peter
Teschner Wolfgang
Arno Butterweck Harald
Koelbl Bernhard
Bruckschwaiger Leopold
Svatos Sonja
Gundinger Thomas
Grausenburger Reinhard
Pljevljakovic Azra
Nürnberger Julia
Original Assignee
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019004482(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxalta Inc filed Critical Baxalta Inc
Publication of MX2019004482A publication Critical patent/MX2019004482A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/12—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the preparation of the feed
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/10—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)

Abstract

Métodos mejorados para manufacturar productos de IVIG. Estos métodos presentan diversas ventajas, tales como la pérdida reducida de lgG durante la purificación y la mejora de la calidad de los productos finales. Composiciones acuosas y farmacéuticas apropiadas para una administración intravenosa, subcutánea y/o intramuscular. Métodos para tratar una enfermedad o una afección, que comprenden administrar una composición de lgG como las que se proveen en la presente.
MX2019004482A 2010-05-26 2012-11-26 Metodo para producir una preparacion de inmunoglobulina con un rendimiento mejorado. MX2019004482A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2010202125A AU2010202125B1 (en) 2010-05-26 2010-05-26 A method to produce an immunoglobulin preparation with improved yield

Publications (1)

Publication Number Publication Date
MX2019004482A true MX2019004482A (es) 2019-08-30

Family

ID=42727304

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2014006981A MX364252B (es) 2010-05-26 2010-05-27 Método para producir una preparación de inmunoglobulina con un rendimiento mejorado.
MX2012013682A MX349815B (es) 2010-05-26 2010-05-27 Metodo para producir una preparacion de inmunoglobulina con un rendimiento mejorado.
MX2012013689A MX337028B (es) 2010-05-26 2011-05-26 Eliminacion de serina proteasas por tratamiento con dioxido de silicona finamente dividido.
MX2019004482A MX2019004482A (es) 2010-05-26 2012-11-26 Metodo para producir una preparacion de inmunoglobulina con un rendimiento mejorado.

Family Applications Before (3)

Application Number Title Priority Date Filing Date
MX2014006981A MX364252B (es) 2010-05-26 2010-05-27 Método para producir una preparación de inmunoglobulina con un rendimiento mejorado.
MX2012013682A MX349815B (es) 2010-05-26 2010-05-27 Metodo para producir una preparacion de inmunoglobulina con un rendimiento mejorado.
MX2012013689A MX337028B (es) 2010-05-26 2011-05-26 Eliminacion de serina proteasas por tratamiento con dioxido de silicona finamente dividido.

Country Status (25)

Country Link
US (6) US8993734B2 (es)
EP (6) EP2554160B1 (es)
JP (6) JP5876474B2 (es)
KR (3) KR101593265B1 (es)
CN (5) CN104958761B (es)
AR (4) AR076800A1 (es)
AU (8) AU2010202125B1 (es)
BR (2) BR112012029893B1 (es)
CA (2) CA2800155A1 (es)
CL (3) CL2012003291A1 (es)
CO (2) CO6660438A2 (es)
DK (3) DK2554160T3 (es)
EA (4) EA023446B1 (es)
ES (4) ES2525492T3 (es)
HK (6) HK1170168A1 (es)
HR (3) HRP20140944T1 (es)
HU (1) HUE064400T2 (es)
IL (2) IL223150A0 (es)
MX (4) MX364252B (es)
MY (3) MY173299A (es)
PL (4) PL2554160T3 (es)
PT (3) PT2554160E (es)
SG (3) SG185724A1 (es)
TW (3) TWI531577B (es)
WO (1) WO2011149472A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI532498B (zh) 2008-03-17 2016-05-11 巴克斯特保健公司 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
MX2012003282A (es) * 2009-09-17 2012-04-30 Baxter Healthcare Sa Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
EA201390156A1 (ru) * 2010-07-23 2014-01-30 Бакстер Интернэшнл Инк. ПРОИЗВОДСТВО ИНТЕР-АЛЬФА-ИНГИБИТОРНЫХ БЕЛКОВ (IaIp) ИЗ ПЛАЗМЫ
CA2832665C (en) * 2011-04-08 2020-01-21 Universidad De Costa Rica Method for producing injectable formulations of blood-derived protein materials, and materials obtained using said method
DK2791675T3 (da) 2011-12-13 2018-07-30 Baxalta GmbH Måling af autoantistoffer under lav ledeevne-betingelser
TWI629283B (zh) * 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
RU2487725C1 (ru) * 2012-03-15 2013-07-20 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации (ФГУП "НПО "Микроген" Минздрава России) Способ получения концентрированного иммуноглобулинового препарата для подкожного введения
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
CN103197053B (zh) * 2013-03-15 2015-02-18 上海市血液中心 一种抗IgA抗体检测试剂盒
CN104072601A (zh) * 2014-07-03 2014-10-01 成都蓉生药业有限责任公司 血液制品中fii沉淀的制备方法
CN104086642A (zh) * 2014-07-03 2014-10-08 成都蓉生药业有限责任公司 血液制品中fi+iii上清的制备方法
CN104086646B (zh) * 2014-07-03 2018-10-09 成都蓉生药业有限责任公司 血液制品中fv沉淀的制备方法
GB201413227D0 (en) * 2014-07-25 2014-09-10 Bioproducts Lab Ltd Process
WO2016064955A1 (en) 2014-10-21 2016-04-28 The General Hospital Corporation Methods of diagnosis and treatment of tuberculosis and infection
CN204424090U (zh) 2014-11-28 2015-06-24 比亚迪股份有限公司 薄膜电容器
CN107921080A (zh) * 2015-04-02 2018-04-17 K·黄 由组分iii制造并纯化出用于静脉注射的凝血酶原复合物浓缩剂的方法以及治疗和预防具有抑制剂的a型血友病或感染了hiv‑1和hiv‑2的b型血友病患者的方法
CN107847541A (zh) * 2015-04-02 2018-03-27 K·黄 克隆并进一步纯化以制备重组静脉注射免疫球蛋白的方法
CN107921079A (zh) * 2015-04-02 2018-04-17 K·黄 由组分iii制造静脉注射免疫球蛋白的方法
CN108495860A (zh) * 2015-09-29 2018-09-04 K·黄 一种从组分iii制备静脉注射免疫球蛋白的方法
WO2017062536A2 (en) * 2015-10-06 2017-04-13 Kieu Hoang A method of manfacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
CN106800583A (zh) * 2015-11-26 2017-06-06 上海洲跃生物科技有限公司 一种速溶无析出的冻干人纤维蛋白原制备工艺
EP3275897A1 (en) 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
WO2018050870A1 (en) * 2016-09-16 2018-03-22 Leukocare Ag A novel method for stabilization of a biopharmaceutical drug product during processing
WO2018050873A1 (en) 2016-09-16 2018-03-22 Leukocare Ag A novel method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN110831627A (zh) * 2017-04-21 2020-02-21 瑞士杰特贝林生物制品有限公司 用于治疗慢性炎症性脱髓鞘性多发性神经病的免疫球蛋白产品
CA3085885A1 (en) * 2017-12-19 2019-06-27 CSL Behring Lengnau AG Protein purification and virus inactivation with alkyl glycosides
JP7465215B2 (ja) * 2018-04-12 2024-04-10 アムジェン インコーポレイテッド 安定なタンパク質組成物を製造する方法
CN108733099B (zh) * 2018-05-31 2020-08-11 上海药明生物技术有限公司 低pH孵育和中和的自动调节系统及方法
WO2021072137A1 (en) * 2019-10-11 2021-04-15 Baxalta Incorporated Heparin-insensitive assay for factor xla
US11439687B2 (en) * 2019-11-04 2022-09-13 Alkahest, Inc. Blood plasma fractions for use in muscle regeneration
AU2021355325A1 (en) * 2020-04-10 2022-11-03 Plasma Technologies, Llc Compositions and methods for simplified high efficiency isolation of proteins
CN111961130B (zh) * 2020-08-31 2021-09-10 华兰生物工程重庆有限公司 一种从血浆中提取并分离IgM和IgG的方法
EP4222161A1 (en) * 2020-10-01 2023-08-09 Takeda Pharmaceutical Company Limited Plasma fractionation process utilizing spray-dried human plasma
WO2022146856A1 (en) * 2020-12-28 2022-07-07 Plasma Technologies, Llc Systems and Methods for Process Scale Isolation of Immunoglobulin G
CN112574296B (zh) * 2020-12-30 2023-05-19 中国医学科学院输血研究所 一种模拟IVIg的多人份混合人血浆IgG样品的分离纯化方法
KR20240040107A (ko) 2021-07-29 2024-03-27 체에스엘 베링 아게 면역글로불린 g를 정제하는 방법 및 이의 용도
CN118434753A (zh) 2021-10-27 2024-08-02 等离子技术有限责任公司 用于分离蛋白质的组合物和方法
KR20230121373A (ko) * 2022-02-11 2023-08-18 주식회사 녹십자 인자 xiii의 정제방법
AU2023230335A1 (en) 2022-03-07 2024-08-29 Takeda Pharmaceutical Company Limited Affinity chromatographic production of clinical human igg products
WO2023170680A1 (en) 2022-03-08 2023-09-14 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system
TW202400621A (zh) 2022-05-02 2024-01-01 日商武田藥品工業股份有限公司 經由超濾自血漿製備科恩池濃縮物之方法
AU2023287493A1 (en) 2022-06-22 2024-10-17 Ageronix SA Alpha1-antitrypsin for use in the treatment of diseases or disorders of the nervous system such as chronic inflammatory demyelinating polyneuropathy
WO2024200757A1 (en) 2023-03-29 2024-10-03 Csl Behring Ag Methods of identifying immunoglobulin associated with adverse reactions

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) * 1942-02-09 1945-12-04 Research Corp Protein product and process
SE348942B (es) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US4056614A (en) 1972-09-22 1977-11-01 Marc Bonneau Immunity depressant medicine
US3998946A (en) * 1975-04-23 1976-12-21 The Regents Of The University Of Minnesota Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same
DE2801123C2 (de) * 1977-01-26 1986-01-02 Armour Pharma GmbH & Co KG, 3440 Eschwege Verfahren zur Herstellung eines intravenös applizierbaren Serumeiweiß-Präparates
US4136094A (en) 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
US4296027A (en) * 1977-08-31 1981-10-20 The Regents Of The University Of Minnesota Pure intravenous human and animal gamma globulins
US4357272A (en) * 1978-03-22 1982-11-02 The South African Inventions Development Corporation Recovering purified antibodies from egg yolk
US4550019A (en) * 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
DE2901822A1 (de) * 1979-01-18 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt
DE2902158A1 (de) 1979-01-20 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung von fibrinogen, einem die gerinnungsfaktoren ii, vii, ix und x enthaltenden prothrombinkomplex, antithrombin iii und einer loesung von lagerstabilen serumproteinen
US4228154A (en) 1979-02-26 1980-10-14 Armour Pharmaceutical Company Purification of plasma albumin by ion exchange chromatography
US4378346A (en) * 1979-08-15 1983-03-29 Tankersley Donald L Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production
US4499073A (en) * 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
JPS5855432A (ja) 1981-09-29 1983-04-01 Fujirebio Inc 静脈注射用免疫グロブリンの製法
US4439358A (en) 1982-06-17 1984-03-27 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US4624780A (en) 1982-06-28 1986-11-25 Alpha Therapeutic Corporation Fractionation of blood plasma
DE3247150A1 (de) 1982-12-21 1984-06-28 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Gerinnungsaktive plasmaproteinloesung, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von stoerungen des haemostasesystems
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US5061237A (en) 1985-07-02 1991-10-29 Cytomed Medizintechnik Gmbh Method of purifying whole blood
DE3523615A1 (de) 1985-07-02 1987-01-15 Cytomed Medizintechnik Medizinisches geraet, insbesondere kanuele, katheter oder implantat
JPH0742235B2 (ja) 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
US5136094A (en) 1988-03-10 1992-08-04 Air Products And Chemicals, Inc. Process for the synthesis of secondary formamides
US5055447A (en) 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
EP0440509A3 (en) * 1990-02-02 1991-12-18 Common Services Agency Novel cell growth medium components and process for producing same
EP0447585B2 (de) * 1990-03-22 2003-05-07 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verträglichen Immunglobulin-G-Präparates
US5130451A (en) * 1991-03-28 1992-07-14 Amoco Corporation Process for preparing carboxyaryl phosphates
US5324425A (en) * 1992-08-26 1994-06-28 Ellison Billy L Method and apparatus for removing solids from aqueous wash solutions
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
FR2711371B1 (fr) 1993-10-18 1995-12-29 Aetsrn Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu.
US5610285A (en) 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AUPN858596A0 (en) 1996-03-08 1996-04-04 Csl Limited Filtration of plasma precipitates using cellulose filter aid
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
US5783640A (en) * 1997-03-04 1998-07-21 The Goodyear Tire & Rubber Company Rubber compositions containing a disodium salt of 2, 2'-dithiosalicyclic acid
TW541179B (en) 1997-03-19 2003-07-11 Green Cross Corp Process for preparing immunoglobulin preparation
GB9705810D0 (en) 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
AT407114B (de) 1997-06-10 2000-12-27 Immuno Ag Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
PT911037E (pt) 1997-10-23 2002-12-31 Mitsubishi Pharma Corp Preparacao de imunoglobulina armazenavel a temperatura ambiente para injeccao intravenosa
US20020114802A1 (en) 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
AT406873B (de) 1998-02-25 2000-10-25 Immuno Ag Verfahren zur abreicherung von pathogenen aus proteinhaltigen lösungen
DE19932782A1 (de) * 1999-07-14 2001-01-18 Biotest Pharma Gmbh Verfahren zur chromatographischen Fraktionierung von Plasma oder Serum, so erhaltene Präparate und deren Verwendung
JP2003511204A (ja) 1999-10-21 2003-03-25 アルコン，インコーポレイティド テノン下薬剤送出
DE10008519C1 (de) 2000-02-21 2001-07-12 Dica Technologies Ag Verfahren und Kommunikationseinrichtungen zum Aufbau von gesicherten E-Mail-Verkehr zwischen Mail-Domains des Internet
DE10008619A1 (de) * 2000-02-24 2001-09-06 Immuno Vet As Lynge Mikroorganismenfreies IgG-Präparat, Verfahren zu seiner Herstellung und seine Verwendung in der Tieraufzucht und in der Tiermast
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
US20020098182A1 (en) 2000-09-28 2002-07-25 Richard Weisbart Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
US20030190732A1 (en) 2000-10-13 2003-10-09 Djuro Josic Plasma fraction containing bikunin, method for the production thereof and use of the same
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
CA2462682A1 (en) 2001-10-04 2003-04-10 Protein Therapeutics, Inc. The use of gammaglobulin for the treatment of immune-mediated diseases
US6893639B2 (en) 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
US7777006B2 (en) 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
KR20060015574A (ko) * 2003-05-23 2006-02-17 노보 노르디스크 헬스 케어 악티엔게젤샤프트 용액 중 단백질 안정화
WO2005012354A1 (en) 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
US20050054003A1 (en) 2003-09-10 2005-03-10 Stenland Christopher J. Prion clearance using particulate metal oxides
JP5010920B2 (ja) 2003-11-08 2012-08-29 プロセラ・バイオロジクス 治療に使用するためのヒト血漿由来のインターα阻害タンパク質の調製方法及びその組成物
KR20070009995A (ko) 2004-01-30 2007-01-19 수오멘 푸나이넨 리스티 베리팔베루 바이러스 안전성 면역글로불린을 제조하는 방법
DK1718675T3 (da) 2004-02-27 2013-07-15 Octapharma Ag Fremgangsmåde til at tilvejebringe en oprenset virussikker antistoftilberedning
WO2006088950A2 (en) 2005-02-14 2006-08-24 University Of Iowa Research Foundation Methods and reagents for treatment and diagnosis of age-related macular degeneration
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
US7807435B2 (en) 2005-08-11 2010-10-05 Baxter International Inc. Method for the purification of alpha-1 proteinase inhibitor (a1PI)
AU2006299293B2 (en) 2005-09-19 2011-08-18 Csl Behring Gmbh Factor H for the treatment of chronic nephropathies and production thereof
FR2894145B1 (fr) 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament
EP1987054A1 (en) * 2006-01-25 2008-11-05 Octapharma AG Purification and use of a factor for supporting wound healing
US8476234B2 (en) 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
EP1852443A1 (en) * 2006-05-05 2007-11-07 Leukocare AG Biocompatible three dimensional matrix for the immobilization of biological substances
DE102007001521A1 (de) * 2007-01-10 2008-07-17 Matthias, Torsten, Dr. Verwendung von Cohn-Oncley-Fraktionen II und II/III zur Behandlung des systemischen Lupus erythematodes
ES2595059T3 (es) * 2007-03-20 2016-12-27 Csl Behring Gmbh Métodos para la producción a escala industrial de preparados terapéuticos del Factor H del complemento a partir de plasma humano
DE202007004346U1 (de) 2007-03-21 2007-10-31 Rehau Ag + Co Rohranordnung
EP2148693A4 (en) * 2007-04-20 2010-06-02 Univ Colorado ALPHA-I-ANTITRYPINE WITHOUT SIGNIFICANT SERINE PROTEASE INHIBITOR ACTIVITY
AU2008261261B2 (en) 2007-06-13 2013-06-27 Csl Behring Gmbh Use of VWF stabilized FVIII preparations and of VWF preparations without FVIII for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
JP5555626B2 (ja) 2007-08-13 2014-07-23 バクスター・インターナショナル・インコーポレイテッド 多発性硬化症、アルツハイマー病およびパーキンソン病を処置するためのケモカインのｉｖｉｇ調節
JP5400050B2 (ja) * 2007-10-02 2014-01-29 シーエスエル、リミテッド 治療用抗体の精製法および使用法
EP3936116A1 (en) 2007-12-28 2022-01-12 Takeda Pharmaceutical Company Limited Rrecombinant vwf containing formulations
CN101249265B (zh) * 2008-04-11 2010-10-27 三九集团湛江开发区双林药业有限公司 静脉注射用人乙肝免疫球蛋白及其制备方法
CA2726281C (en) 2008-05-28 2023-04-18 Prothera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from blood
KR101507718B1 (ko) 2008-06-24 2015-04-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체
CN201169579Y (zh) * 2008-06-30 2008-12-24 山东泰邦生物制品有限公司 一种人血白蛋白分离用乙醇雾化扩散装置
PT2349314E (pt) 2008-10-21 2013-05-28 Baxter Int Formulações de vwf recombinante liofilizado
CA2742994A1 (en) 2008-11-12 2010-05-20 Baxter International Inc. Purification of butyrylcholinesterase using membrane adsorption
TWI445714B (zh) 2009-05-27 2014-07-21 Baxter Int 產製用於皮下使用之高濃度免疫球蛋白製備物之方法
US8304524B2 (en) 2009-07-23 2012-11-06 Baxter International Inc. Manufacture of factor H (FH) and FH-derivatives from plasma
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
TWI670073B (zh) 2010-07-08 2019-09-01 美商巴克斯歐塔公司 在細胞培養物中生產重組高分子量ｖＷＦ的方法
EA201390156A1 (ru) 2010-07-23 2014-01-30 Бакстер Интернэшнл Инк. ПРОИЗВОДСТВО ИНТЕР-АЛЬФА-ИНГИБИТОРНЫХ БЕЛКОВ (IaIp) ИЗ ПЛАЗМЫ

Also Published As

Publication number Publication date
EP2803349A1 (en) 2014-11-19
CA2800155A1 (en) 2011-12-01
CN103068365A (zh) 2013-04-24
AU2020200373A1 (en) 2020-02-13
HK1170168A1 (en) 2013-02-22
AU2024204779A1 (en) 2024-08-01
JP2013527201A (ja) 2013-06-27
JP2013528183A (ja) 2013-07-08
EP2575762A2 (en) 2013-04-10
AU2010202125B1 (en) 2010-09-02
HK1181682A1 (en) 2013-11-15
AR121861A2 (es) 2022-07-20
HK1203838A1 (en) 2015-11-06
IL223150A0 (en) 2013-02-03
EP2803349C0 (en) 2023-09-27
EA201291367A1 (ru) 2013-09-30
KR101593265B1 (ko) 2016-02-11
PL2554160T3 (pl) 2015-07-31
US8993734B2 (en) 2015-03-31
SG185724A1 (en) 2013-01-30
EP2554160B1 (en) 2015-02-25
AU2016202973A1 (en) 2016-05-26
CO6660438A2 (es) 2013-04-30
TWI504607B (zh) 2015-10-21
EP4039249A1 (en) 2022-08-10
HUE064400T2 (hu) 2024-03-28
CN104958761A (zh) 2015-10-07
MY161617A (en) 2017-04-28
JP2018080207A (ja) 2018-05-24
US11136350B2 (en) 2021-10-05
EP2554160A1 (en) 2013-02-06
BR112012029897A2 (pt) 2016-08-16
HRP20141109T1 (hr) 2014-12-19
PT2445482E (pt) 2014-11-03
MX2012013682A (es) 2013-01-28
SG10201505161SA (en) 2015-08-28
KR101716534B1 (ko) 2017-03-14
CL2012003290A1 (es) 2013-10-18
EA201291355A1 (ru) 2013-04-30
TWI543989B (zh) 2016-08-01
EP2575762B1 (en) 2014-07-09
PT2575762E (pt) 2014-07-28
PL2803349T3 (pl) 2024-02-26
JP2016053016A (ja) 2016-04-14
AU2021286395B2 (en) 2024-04-11
AU2010224461B2 (en) 2011-08-04
CA2800272A1 (en) 2011-12-01
AU2018201371A1 (en) 2018-03-22
US20180118782A1 (en) 2018-05-03
EP2796128A1 (en) 2014-10-29
HK1183449A1 (en) 2013-12-27
MX349815B (es) 2017-08-09
CN104840946A (zh) 2015-08-19
AR114228A2 (es) 2020-08-05
AU2011258111B2 (en) 2016-02-11
WO2011149472A1 (en) 2011-12-01
KR20130109016A (ko) 2013-10-07
AU2020200373B2 (en) 2022-01-13
IL223149A0 (en) 2013-02-03
EP2803349B1 (en) 2023-09-27
AU2018201371B2 (en) 2019-10-31
EP2445482B1 (en) 2014-08-27
EA034530B1 (ru) 2020-02-18
EP2445482A1 (en) 2012-05-02
HK1215931A1 (zh) 2016-09-30
EA034602B1 (ru) 2020-02-25
ES2536093T3 (es) 2015-05-20
US20130101579A1 (en) 2013-04-25
PL2575762T3 (pl) 2015-01-30
BR112012029893B1 (pt) 2022-09-06
KR101647617B1 (ko) 2016-08-10
TW201141879A (en) 2011-12-01
SG185725A1 (en) 2012-12-28
TW201202263A (en) 2012-01-16
US8940877B2 (en) 2015-01-27
AU2021286395A1 (en) 2022-01-20
DK2554160T3 (da) 2015-04-27
CL2014003430A1 (es) 2015-05-04
EA025826B1 (ru) 2017-02-28
ES2505465T3 (es) 2014-10-10
DK2575762T3 (da) 2014-10-13
AR082093A1 (es) 2012-11-14
JP5876474B2 (ja) 2016-03-02
PL2445482T3 (pl) 2015-01-30
MX2012013689A (es) 2013-01-28
MY160551A (en) 2017-03-15
AU2010224461A1 (en) 2010-10-21
US20210403504A1 (en) 2021-12-30
EA201691558A1 (ru) 2017-05-31
CN109180776B (zh) 2022-12-13
HK1213790A1 (zh) 2016-07-15
IL223149A (en) 2017-02-28
US20240117009A1 (en) 2024-04-11
ES2959234T3 (es) 2024-02-22
MX364252B (es) 2019-04-17
CL2012003291A1 (es) 2013-10-04
JP2016155798A (ja) 2016-09-01
JP2017014297A (ja) 2017-01-19
JP6363676B2 (ja) 2018-07-25
KR20160014119A (ko) 2016-02-05
BR112012029893A2 (pt) 2019-05-28
US20110293638A1 (en) 2011-12-01
EA201500848A1 (ru) 2016-06-30
AU2016202973B2 (en) 2017-12-07
TWI531577B (zh) 2016-05-01
DK2445482T3 (da) 2014-09-22
EA023446B1 (ru) 2016-06-30
HRP20140944T1 (hr) 2014-12-05
HRP20150484T1 (hr) 2015-08-14
AU2011258111A1 (en) 2012-12-13
AR076800A1 (es) 2011-07-06
CN102970975B (zh) 2015-05-06
MY173299A (en) 2020-01-14
KR20130080450A (ko) 2013-07-12
ES2525492T3 (es) 2014-12-23
US20150133644A1 (en) 2015-05-14
JP6592120B2 (ja) 2019-10-16
JP5866345B2 (ja) 2016-02-17
MX337028B (es) 2016-02-09
PT2554160E (pt) 2015-06-11
CN102970975A (zh) 2013-03-13
CN103068365B (zh) 2015-07-08
CO6660439A2 (es) 2013-04-30
TW201542584A (zh) 2015-11-16
CN109180776A (zh) 2019-01-11
CN104958761B (zh) 2021-01-01

Similar Documents

Publication Publication Date Title
MX2019004482A (es) Metodo para producir una preparacion de inmunoglobulina con un rendimiento mejorado.
MX2014001372A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2009129246A3 (en) Compositions and methods for preparing and using same
MX2015006681A (es) Formulaciones de vancomicina estabilizadas.
MD20140035A2 (ro) Metodă de tratament al hepatitei virale C
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
MX2019000547A (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
TN2014000185A1 (en) Polyethylene glycol based prodrug of adrenomedullin and use thereof
MX2011005865A (es) Clorhidrato de nalmefeno dihidratado.
WO2012017324A3 (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
EP2699584A4 (en) CYCLIC PEPTIDE FROM NONOMURAEA SP., METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF MICRO-BACTERIA-INFLAMMATED DISEASES THEREWITH
WO2013080217A3 (en) Crystalline forms of carbazitaxel and process for preparation thereof
WO2012135848A3 (en) Melatonin-based treatment and diagnosis of bile duct disease
MX2017016231A (es) Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina.
WO2012063269A3 (en) Process for preparing iloperidone
IN2014DN03010A (es)
MX2014015340A (es) Composiciones y metodos para tratar o evitar infeccion por pneumovirus y enfermedades asociadas.
WO2010101301A9 (en) Prophylaxis and treatment of macular degeneration and retinopathy using a prdx protein
WO2012177075A3 (ko) 항생제 및 라이소포스파티딜콜린을 포함하는 면역 증강 또는 세균성 감염 질환 치료용 조성물
WO2012122451A3 (en) Polymorphs of maxacalcitol and process for the preparation of maxacalcitol
MX2014000870A (es) Composiciones farmaceuticas que comprenden 4-bromo-n-(imidazolidin -2-iliden)-1h-benzimidazol-5-amina para tratar enfermedades de la retina.
WO2012158776A3 (en) Combination therapy for treatment of cancer
WO2015065628A3 (en) Laquinimod combination therapy for treatment of multiple sclerosis